Marat Fudim, MD
Cardiovascular Disease · Durham, NCNPI 1013262419
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (46.2%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. It is spread thinly across 37 manufacturers, the largest accounting for just 15.5%. 2025 is the largest year on record at $341,216, more than ten times the $1,025 reported in 2019. Among cardiovascular disease clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 769 payments — averaging $1173.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$139K
- Boston Scientific$101K
- Bayer$94K
- Novo Nordisk$68K
- Medtronic$60K
- Novo Nordisk AS$58K
- plus $383K from 31 others
Across 13 payments — averaging $36,908 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Procyrion, Inc.$207K
- BTG International Inc.$171K
- Endotronix, Inc.$53K
- Astrazeneca UK Limited$23K
- Daxor Corporation$15K
- Bayer$9K
- plus $1K from 1 others
What the payments were for
- Consulting fees$416,54846%
- Speaking & faculty fees$343,35238%
- Grants$1000%
- Travel & lodging$119,49313%
- Food & beverage$22,4532%
- Education$780%
- Other$4290%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 130 | $139,491 |
| Boston Scientific | 99 | $100,948 |
| Bayer | 49 | $93,986 |
| Novo Nordisk | 48 | $67,658 |
| Medtronic(2 entities) | 72 | $59,557 |
| Novo Nordisk AS | 20 | $57,687 |
| Cvrx, Inc. | 81 | $47,927 |
| Pharmacosmos Therapeutics Inc. | 12 | $42,277 |
| Procyrion, Inc. | 5 | $34,694 |
| Lexicon Pharmaceuticals, Inc. | 29 | $30,300 |
| Endotronix, Inc. | 7 | $26,489 |
| Abbott | 60 | $26,083 |
| ZOLL Respicardia, Inc. | 12 | $26,065 |
| Impulse Dynamics (USA) Inc. | 29 | $24,589 |
| Daxor Corporation | 12 | $22,390 |
| Boehringer Ingelheim | 13 | $22,375 |
| Scpharmaceuticals Inc. | 6 | $12,332 |
| E.r. Squibb & Sons, L.L.C. | 6 | $11,973 |
| Edwards Lifesciences | 15 | $10,058 |
| Merck | 9 | $8,671 |
| Analog Devices Inc. | 4 | $8,098 |
| ZOLL Circulation Inc | 9 | $7,400 |
| Terumo Medical Corporation | 6 | $6,300 |
| Recor Medical Inc | 7 | $3,816 |
| GSK | 3 | $3,100 |
| Chugai Pharmaceutical Co., Ltd. | 3 | $2,415 |
| AstraZeneca | 6 | $1,963 |
| Biotronik Inc. | 2 | $1,220 |
| Boehringer Ingelheim International GmbH | 5 | $880 |
| Pacira Pharmaceuticals Incorporated | 1 | $560 |
| Eko Health, Inc. | 1 | $429 |
| Vertex | 1 | $253 |
| Itamar Medical Inc | 3 | $145 |
| Novartis | 1 | $139 |
| Philips North America LLC | 1 | $79 |
| Abiomed | 1 | $62 |
| Amgen | 1 | $50 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LifeVest$137,850
- Kerendia$75,491
- OPTIMIZER$47,836
- Barostim Neo System$46,765
- GENERAL - THERAPIES$42,312
- Monoferric$42,204
- AORTIX SYSTEM$34,621
- Inpefa$29,530
- SYMPLICITY G3$28,005
- remede System$26,008
- BVA-100$20,371
- I-STAT$15,585
- CORDELLA PULOMONARY ARTERY PRESSURE SENSOR$14,798
- GENERAL - STRUCTURAL HEART$12,500
- FUROSCIX$12,312
- CORDELLA PULMONARY ARTERY PRESSURE SENSOR$11,671
- COREVALVE EVOLUT R$9,556
- CARDIOMEMS$8,547
- Sensinel CPM Wearable$8,000
- JARDIANCE$7,804
How this compares
$902,454 in reported general payments places this provider in the 95th percentile of 727 cardiovascular disease providers in North Carolina.
See all cardiovascular disease providers in North Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AdempasRiociguat | 12 | $169,323 |
| JardianceEmpagliflozin | 91 | $116,814 |
| OzempicSemaglutide | 110 | $114,215 |
| EntrestoSacubitril/Valsartan | 86 | $87,759 |
| FarxigaDapagliflozin Propanediol | 65 | $68,549 |
| EliquisApixaban | 47 | $47,687 |
| VerquvoVericiguat | 36 | $38,793 |
| LokelmaSodium Zirconium Cyclosilicate | 13 | $18,809 |
| InpefaSotagliflozin | 24 | $18,780 |
| MounjaroTirzepatide | 12 | $13,451 |
| Midodrine Hcl | 31 | $4,819 |
| Droxidopa | 13 | $1,867 |
| Torsemide | 55 | $1,804 |
| Eplerenone | 13 | $1,036 |
| Spironolactone | 131 | $869 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BayerAdempas | $93,986 | $169,32312 claims |
| Boehringer IngelheimJardiance | $22,375 | $116,81491 claims |
| Novo NordiskOzempic | $67,658 | $114,215110 claims |
| NovartisEntresto | $139 | $87,75986 claims |
| AstraZenecaFarxiga, Lokelma | $1,963 | $87,35978 claims |
| MerckVerquvo | $8,671 | $38,79336 claims |
| Lexicon Pharmaceuticals, Inc.Inpefa | $30,300 | $18,78024 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 727 cardiovascular disease providers in North Carolina.
Other cardiovascular disease in Durham
- R WilliamsDurham$2.1M
- Jonathan PicciniDurham$767K
- Robert MentzDurham$489K
- Adrian HernandezDurham$409K
- Neha PagidipatiDurham$301K
- Joseph KissloDurham$283K
- Mitchell KrucoffDurham$281K
- Ankeet BhattDurham$258K
- Christopher GrangerDurham$257K
- Gary FelkerDurham$256K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.